Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives Consensus Rating of "Buy" from Brokerages

Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) have earned an average rating of "Buy" from the six analysts that are covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have covered the stock in the last year is $5.33.

Several analysts recently weighed in on CLSD shares. Needham & Company LLC restated a "buy" rating and issued a $6.00 price target on shares of Clearside Biomedical in a research note on Wednesday, November 13th. HC Wainwright restated a "buy" rating and issued a $6.00 price target on shares of Clearside Biomedical in a research note on Thursday, November 14th. Chardan Capital restated a "buy" rating and issued a $6.00 price target on shares of Clearside Biomedical in a research note on Friday, November 15th. Finally, StockNews.com raised Clearside Biomedical from a "sell" rating to a "hold" rating in a research report on Thursday, December 12th.

Clearside Biomedical Stock Performance

Shares of Clearside Biomedical stock traded up $0.05 during midday trading on Friday, hitting $0.85. The company had a trading volume of 186,194 shares, compared to its average volume of 397,711. The stock has a market capitalization of $64.47 million, a P/E ratio of -1.89 and a beta of 2.10. The company has a 50 day moving average of $0.96 and a 200 day moving average of $1.06. Clearside Biomedical has a 52-week low of $0.77 and a 52-week high of $2.12.

Remove Ads

Hedge Funds Weigh In On Clearside Biomedical

Hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC lifted its holdings in shares of Clearside Biomedical by 8.8% during the 3rd quarter. Geode Capital Management LLC now owns 731,386 shares of the company's stock valued at $929,000 after buying an additional 59,089 shares during the period. Johnson & Johnson bought a new position in shares of Clearside Biomedical during the 3rd quarter valued at $105,000. Northern Trust Corp lifted its holdings in shares of Clearside Biomedical by 24.0% during the 4th quarter. Northern Trust Corp now owns 165,499 shares of the company's stock valued at $157,000 after buying an additional 32,048 shares during the period. Finally, Investor s Fiduciary Advisor Network LLC bought a new position in shares of Clearside Biomedical during the 4th quarter valued at $32,000. 18.75% of the stock is owned by institutional investors.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.